Immuron Limited’s (ASX:IMC) (NASDAQ:IMRN) flag-ship product Travelan® has achieved a revenue in excess of $914,000 for the first six months of FY2018, experiencing strong sales growth in both the U.S. and Australia.
Travelan is a natural product, specifically designed to reduce the risk of infection by E.coli, the most common cause of travellers’ diarrhoea or Bali Belly.
The company sold $335,000 worth of Travelan in the U.S. market during H1 FY2018, representing a 250% increase on the same period last year.
Travelan had $579,000 in sales in the Australian market, representing a 27% increase on the same period last year.
New clinical study of IMM-529
Immuron is also developing and commercializing other oral immunetherapeutics for the treatment of gut related diseases.
Last month, the company enrolled the first patients into its first-in-human IMM-529 clinical study for the treatment of clostridium difficile infection (CDI).
Most commonly affecting older adults after use of antibiotic medications, CDI can cause symptoms that range from diarrhea to life-threatening gut inflammation.
IMM-529 uses a combination of polyclonal antibodies to target and neutralise the three main virulence factors of CDI without negatively impacting the microbiome.
Clostridium-difficile infection is a multi-billion dollar market
According to the Centers for Disease Control and Prevention (CDC), clostridium-difficile infects more than 450,000 patients causing over 29,000 deaths per year in the U.S alone.
There is a high likelihood for recurrence of symptoms, which nearly triples the healthcare costs per patient, resulting in annual healthcare costs of nearly $4.5 billion.